On the basis of our experience ranging from fundamental research to clinical development,
we are expanding collaborative development projects with other institutes and companies.
Our collaborative research and development projects are as follows:
LTT Bio- Pharma intends to make the most of its research material (approved drug library), DR expertise, and research funding for effective application of your basic research findings to clinical use. Therefore, we are seeking proposals for joint DR screening with us from Japanese researchers.
Drug repositioning (DR) is a drug discovery strategy to discover new pharmacological effects of approved drugs for indication expansion. Our own library of approved medicines stores only drugs commercially available in Japan (approved drugs). We are seeking collaborative DR-based research and development proposals that approved drugs having the pharmacological effects you are interested in are discovered using our approved drug library, and the effects will be examined in clinical practice.
As a pioneer of drug delivery system (DDS) research, we have led growth in this area. Our DDS product, lipo-PGE1 achieved a sales peak of over 50 billion yen, and now we have various DDS technologies and promote development of new technologies. We are seeking collaborative research and development proposals for DDS products for improvement of the safety and efficacy of your candidate drugs.
Our PC-SOD currently under development is the only SOD product that can be administered to humans. PC-SOD products are expected to be effective for various diseases because it can remove the active oxygen species that cause many types of diseases. In addition, we will seek collaborative research and development proposals for additional indications for pharmaceutical products developed by LTT Bio- Pharma.
Find out more about licensing out our pipelines to other companies, licensing in of your candidate drugs to LTT Bio- Pharma, and collaborative development of these candidate drugs as follows.
＜From LTT to other companies＞LTT has a goal to License out our pipelines under development to other companies as early as possible. Some of them have already proceeded to phase II clinical trials.
＜From other institutes to LTT＞As a pioneer in drug discovery-related bio-ventures in Japan, we have successful experience and know-how in many pharmaceutical developments. Our experienced employees, specialists for nonclinical trials, clinical trials, drug manufacturing, or IP management can help you deliver your candidate drugs to patients. In addition we will consider collaborative development of your pipelines under development, if we have the expertise, human resources, and funding to help in the development. For example, in March 2018, we concluded a collaborative development agreement with Nobelpharma Co., Ltd., and initiated a joint development program for DR-related pharmaceutical products.
We support your medical business in China in cooperation with Beijing Tide Pharmaceutical.
Beijing Tide Pharmaceutical, which LTT Bio- Pharma founded with a Chinese government-related hospital more than 20 years ago, has grown into one of China’s leading pharmaceutical companies (among the best 20 in the profits). The company has been noted for excellent sales performance by more than 1,300 MRs and sales networks throughout the country, and its outstanding developmental ability has brought about successful launching of many pharmaceuticals in China. Recently, it has been expanding its business into the various fields of medical devices or hospitals (medical devices, health food products). Utilizing these advantages, we will support you in expanding your medical business in China, such as development or marketing of pharmaceutical products or to License out your products to Beijing Tide Pharmaceutical in cooperation with Beijing Tide Pharmaceutical.